biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	5/18/2017 2:14:50 PM
	Read Replies (1) of 3661

Double ASCO whammy, LPTX.... microcap, ASCO abstract shows significant toxicity in lead program (dickkopf1-specific MAb). Moreover, Amgen reports no single agent activity from anti-GITR, and lptx's second program is anti-GITR. Off 13% at the moment, was off > 15% earlier. I took a modest position, hoping for enthusiasm at meeting. Recent dickkopf-1 literature looks interesting, and BMY's ASCO abstract, anti-GITR plus anti-PD-1, looks encouraging. As always... I trade, and any given position which I discuss could be gone before anyone reads said discussion.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next